DSpace Fukushima Medical University

福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.54 (2008) >

Please use this identifier to cite or link to this item: http://ir.fmu.ac.jp/dspace/handle/123456789/227

Files in This Item:

File Description SizeFormat
FksmJMedSci_54_p61.pdf1.64 MBAdobe PDFDownload
Title: Expression of secretoglobin3A2 (SCGB3A2) in primary pulmonary carcinomas
Other Titles: SCGB3A2 expression in primary lung cancers
Authors: Tachihara-Yoshikawa, Motoko
Ishida, Takashi
Watanabe, Kana
Sugawara, Aya
Kanazawa, Kenya
Kanno, Ryuzo
Suzuki, Toshimitsu
Niimi, Tomoaki
Kimura, Shioko
Munakata, Mitsuru
Affiliation: 呼吸器内科学講座
外科学第一講座
病理学第二講座
Source title: Fukushima Journal of Medical Science
Volume: 54
Issue: 2
Start page: 61
End page: 72
Issue Date: Dec-2008
Abstract: Secretoglobin (SCGB) 3A2 is a downstream target gene for the thyroid transcription factor-1 (TITF1). SCGB3A2 plays a role as an anti-inflammatory agent, however, its role in primary pulmonary carcinomas has not been examined. We assessed immunohistochemical expression of SCGB3A2 in primary pulmonary carcinomas and evaluated the correlation between the expression and histopathological phenotypes and prognosis. One hundred and fifty-six primary lung cancers undergone for surgical resection were examined. The percentages of SCGB3A2 positive cells were scored and tumors had immunoreactivity in more than 10% of tumor cells were considered positive for SCGB3A2. Overall reactivity for SCGB3A2 was observed in 116 (74.4%) of 156 primary lung cancers. SCGB3A2 was predominantly expressed in adenocarcinomas (86.5%), compared with squamous cell carcinomas (50.0%) and small cell carcinomas (42.9%). The expression in papillary adenocarcinomas was seen at higher frequency than that in tubular adenocarcinomas. There was no significant relationship between SCGB3A2 expression and tumor differentiation, and pathological stage. Positive expression of SCGB3A2 was not associated with better survival rate. SCGB3A2 expression in primary pulmonary carcinomas is high, especially in adenocarcinomas. Our results indicate that SCGB3A2 has a potential to be a specific and useful marker for primary pulmonary adenocarcinomas.
Publisher: The Fukushima Society of Medical Science
Publisher (Alternative foam): 福島医学会
language: eng
URI: http://ir.fmu.ac.jp/dspace/handle/123456789/227
Full text URL: http://ir.fmu.ac.jp/dspace/bitstream/123456789/227/1/FksmJMedSci_54_p61.pdf
ISSN: 0016-2590
PubMed ID: 19418968
Rights: © 2008 The Fukushima Society of Medical Science
Appears in Collections:Vol.54 (2008)

Files in This Item:

File Description SizeFormat
FksmJMedSci_54_p61.pdf1.64 MBAdobe PDFDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard